In this issue:
Nivolumab for R/R DLBCL ineligible for ASCT
Stem-cell transplant with nicotinamide-expanded cord blood
Venetoclax-rituximab in R/R CLL
Double-hit gene expression signature defines
GCB-DLBCL subgroup PET-adapted treatment for Hodgkin lymphoma
Axicabtagene ciloleucel in large B-cell lymphoma
Ibrutinib + obinutuzumab in CLL
Ibrutinib + nivolumab in NHL or CLL
GVHD prophylaxis + ATLG after alloHSCT for AML
Tamibarotene improves relapse-free survival of APL
Please login below to download this issue (PDF)